Find Clinical Trial

Long-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5/5/7.5 mg b.i.d.) on top of anti-anginal background therapy, to patients with chronic stable angina pectoris. An international, double-blind placebo controlled study.


← Back
Study Phase

Phase 3

Therapeutic Area

Cardiovascular Diseases

IndicationCoronary Artery Disease
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

IVABRADINE,
S016257

Active Substance CodeS016257
Protocol CodeCL3-16257-067
EudraCT Code2006-005475-17
ISRCTN CodeISRCTN99185656


Documents and links

Results summary READ MORE
Scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility